Related Experiment Videos
Influence of Cholografin and Renografin 76 on platelet function
Insights
High levels of contrast agents like Cholografin and Renografin 76 can inhibit platelet aggregation. However, this effect on platelet function did not lead to significant bleeding complications in patients undergoing angiography.
Area of Science:
- Medical Imaging
- Hematology
- Pharmacology
Background:
- Iodinated contrast agents are widely used in medical imaging.
- Understanding their potential effects on hemostasis is crucial for patient safety.
- Previous studies have suggested possible interactions between contrast media and platelet function.
Purpose of the Study:
- To investigate the in vitro and in vivo effects of Cholografin and Renografin 76 on platelet aggregation.
- To assess the clinical significance of contrast agent-induced platelet inhibition on bleeding complications.
Main Methods:
- In vitro platelet aggregation assays were performed using varying concentrations of Cholografin and Renografin 76.
- Plasma samples from patients undergoing intravenous cholangiography (Cholografin) and angiography (Renografin 76) were analyzed.
- Platelet aggregation, bleeding times, and bleeding complications were evaluated in patient cohorts.
Main Results:
- Both Cholografin and Renografin 76 demonstrated significant in vitro inhibition of platelet aggregation at specific concentrations.
- Patients receiving Cholografin or Renografin 76 for non-cardiac procedures showed minimal plasma contrast agent levels and unimpaired hemostasis.
- Patients undergoing cardiac angiography with Renografin 76 exhibited platelet aggregation inhibition at high contrast agent levels, but without prolonged bleeding or complications.
Conclusions:
- High plasma concentrations of iodinated contrast agents can inhibit platelet aggregation both in vitro and in vivo.
- Despite in vitro and in vivo platelet inhibition, clinically significant bleeding complications were not observed in the studied patient populations.
- The findings suggest that while contrast agents can affect platelet function, this is unlikely to cause major bleeding issues in routine clinical practice.
Abstract:
Cholografin and Renografin 76 were studied to determine their effects on platelet function. In vitro platelet aggregation was significantly inhibited by at least 3.4 micron/ml Cholografin and 19.5 micron/ml Renografin 76. Patients who received Cholografin for intravenous cholangiography, and Renografin 76 for non-cardiac angiography, had low levels of plasma contrast agent, and hemostasis was clinically unimpaired. Patients who received Renografin 76 for cardiac angiography had inhibition of platelet aggregation at high levels of plasma contrast agent; there was no correlation with prolonged bleeding times, or with bleeding complications. High levels of plasma contrast agent may inhibit platelet aggregation in vitro and in vivo, although this may not be associated with clinically significant bleeding.